Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
60
SNSE Quote, Financials, Valuation and Earnings
Last price:
$9.27
Seasonality move
:
-6.39%
Day range:
$9.10 - $9.45
52-week range:
$5.00 - $18.35
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
0.43x
Volume:
22.5K
Avg. volume:
89.7K
1-year change:
5.91%
Market cap:
$11.6M
Revenue:
--
EPS (TTM):
-$10.67
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SNSE
Sensei Biotherapeutics, Inc.
|
-- | -$3.34 | -- | -50.77% | $32.50 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
NNVC
NanoViricides, Inc.
|
-- | -$0.08 | -- | -42.49% | $6.50 |
|
OGEN
Oragenics, Inc.
|
-- | -- | -- | -- | $2.00 |
|
PTN
Palatin Technologies
|
-- | -$0.17 | -- | -67.93% | -- |
|
TOVX
Theriva Biologics, Inc.
|
-- | -$0.38 | -- | -94.42% | $7.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SNSE
Sensei Biotherapeutics, Inc.
|
$9.21 | $32.50 | $11.6M | -- | $0.00 | 0% | -- |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$4.57 | $0.85 | $575.9M | 7.68x | $0.80 | 0% | 8.88x |
|
NNVC
NanoViricides, Inc.
|
$1.20 | $6.50 | $21.6M | -- | $0.00 | 0% | -- |
|
OGEN
Oragenics, Inc.
|
$0.83 | $2.00 | $682.6K | -- | $0.00 | 0% | 0.53x |
|
PTN
Palatin Technologies
|
$0.09 | -- | $2.4M | -- | $0.00 | 0% | -- |
|
TOVX
Theriva Biologics, Inc.
|
$0.20 | $7.00 | $6.8M | -- | $0.00 | 0% | 0.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SNSE
Sensei Biotherapeutics, Inc.
|
8.57% | 1.626 | 23.66% | 7.39x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | 2.113 | 8.08% | 1.85x |
|
NNVC
NanoViricides, Inc.
|
-- | 0.464 | -- | 0.95x |
|
OGEN
Oragenics, Inc.
|
3.86% | -0.075 | 36.62% | 3.97x |
|
PTN
Palatin Technologies
|
-- | 1.358 | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
29.07% | -3.365 | 66.16% | 0.68x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SNSE
Sensei Biotherapeutics, Inc.
|
-$37K | -$5.2M | -62.44% | -68.55% | -- | -$5.9M |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
NNVC
NanoViricides, Inc.
|
-$132.8K | -$1.8M | -92.29% | -92.29% | -- | -$1.7M |
|
OGEN
Oragenics, Inc.
|
-- | -$3.1M | -311.49% | -509.23% | -- | -$3M |
|
PTN
Palatin Technologies
|
-- | -- | -- | -- | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
-$28K | -$4.4M | -148.18% | -171.04% | -- | -$4.3M |
Sensei Biotherapeutics, Inc. vs. Competitors
-
Which has Higher Returns SNSE or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -- compared to Sensei Biotherapeutics, Inc.'s net margin of -255.85%. Sensei Biotherapeutics, Inc.'s return on equity of -68.55% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital SNSESensei Biotherapeutics, Inc.-- -$3.91 $29.9M NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About SNSE or NBY?
Sensei Biotherapeutics, Inc. has a consensus price target of $32.50, signalling upside risk potential of 280.02%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -81.4%. Given that Sensei Biotherapeutics, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Sensei Biotherapeutics, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SNSESensei Biotherapeutics, Inc.1 0 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is SNSE or NBY More Risky?
Sensei Biotherapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.
-
Which is a Better Dividend Stock SNSE or NBY?
Sensei Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Sensei Biotherapeutics, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SNSE or NBY?
Sensei Biotherapeutics, Inc. quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Sensei Biotherapeutics, Inc.'s net income of -$4.9M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Sensei Biotherapeutics, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 7.68x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sensei Biotherapeutics, Inc. is -- versus 8.88x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SNSESensei Biotherapeutics, Inc.-- -- -- -$4.9M NBYNovaBay Pharmaceuticals, Inc.8.88x 7.68x $521K -$1.3M
-
Which has Higher Returns SNSE or NNVC?
NanoViricides, Inc. has a net margin of -- compared to Sensei Biotherapeutics, Inc.'s net margin of --. Sensei Biotherapeutics, Inc.'s return on equity of -68.55% beat NanoViricides, Inc.'s return on equity of -92.29%.
Company Gross Margin Earnings Per Share Invested Capital SNSESensei Biotherapeutics, Inc.-- -$3.91 $29.9M NNVCNanoViricides, Inc.-- -$0.10 $7.2M -
What do Analysts Say About SNSE or NNVC?
Sensei Biotherapeutics, Inc. has a consensus price target of $32.50, signalling upside risk potential of 280.02%. On the other hand NanoViricides, Inc. has an analysts' consensus of $6.50 which suggests that it could grow by 441.67%. Given that NanoViricides, Inc. has higher upside potential than Sensei Biotherapeutics, Inc., analysts believe NanoViricides, Inc. is more attractive than Sensei Biotherapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SNSESensei Biotherapeutics, Inc.1 0 0 NNVCNanoViricides, Inc.1 0 0 -
Is SNSE or NNVC More Risky?
Sensei Biotherapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NanoViricides, Inc. has a beta of 1.158, suggesting its more volatile than the S&P 500 by 15.816%.
-
Which is a Better Dividend Stock SNSE or NNVC?
Sensei Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NanoViricides, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sensei Biotherapeutics, Inc. pays -- of its earnings as a dividend. NanoViricides, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SNSE or NNVC?
Sensei Biotherapeutics, Inc. quarterly revenues are --, which are smaller than NanoViricides, Inc. quarterly revenues of --. Sensei Biotherapeutics, Inc.'s net income of -$4.9M is lower than NanoViricides, Inc.'s net income of -$1.8M. Notably, Sensei Biotherapeutics, Inc.'s price-to-earnings ratio is -- while NanoViricides, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sensei Biotherapeutics, Inc. is -- versus -- for NanoViricides, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SNSESensei Biotherapeutics, Inc.-- -- -- -$4.9M NNVCNanoViricides, Inc.-- -- -- -$1.8M
-
Which has Higher Returns SNSE or OGEN?
Oragenics, Inc. has a net margin of -- compared to Sensei Biotherapeutics, Inc.'s net margin of --. Sensei Biotherapeutics, Inc.'s return on equity of -68.55% beat Oragenics, Inc.'s return on equity of -509.23%.
Company Gross Margin Earnings Per Share Invested Capital SNSESensei Biotherapeutics, Inc.-- -$3.91 $29.9M OGENOragenics, Inc.-- -$1.96 $10.2M -
What do Analysts Say About SNSE or OGEN?
Sensei Biotherapeutics, Inc. has a consensus price target of $32.50, signalling upside risk potential of 280.02%. On the other hand Oragenics, Inc. has an analysts' consensus of $2.00 which suggests that it could grow by 141.11%. Given that Sensei Biotherapeutics, Inc. has higher upside potential than Oragenics, Inc., analysts believe Sensei Biotherapeutics, Inc. is more attractive than Oragenics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SNSESensei Biotherapeutics, Inc.1 0 0 OGENOragenics, Inc.1 0 0 -
Is SNSE or OGEN More Risky?
Sensei Biotherapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Oragenics, Inc. has a beta of 0.922, suggesting its less volatile than the S&P 500 by 7.781%.
-
Which is a Better Dividend Stock SNSE or OGEN?
Sensei Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sensei Biotherapeutics, Inc. pays -- of its earnings as a dividend. Oragenics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SNSE or OGEN?
Sensei Biotherapeutics, Inc. quarterly revenues are --, which are smaller than Oragenics, Inc. quarterly revenues of --. Sensei Biotherapeutics, Inc.'s net income of -$4.9M is lower than Oragenics, Inc.'s net income of -$3.1M. Notably, Sensei Biotherapeutics, Inc.'s price-to-earnings ratio is -- while Oragenics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sensei Biotherapeutics, Inc. is -- versus 0.53x for Oragenics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SNSESensei Biotherapeutics, Inc.-- -- -- -$4.9M OGENOragenics, Inc.0.53x -- -- -$3.1M
-
Which has Higher Returns SNSE or PTN?
Palatin Technologies has a net margin of -- compared to Sensei Biotherapeutics, Inc.'s net margin of --. Sensei Biotherapeutics, Inc.'s return on equity of -68.55% beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SNSESensei Biotherapeutics, Inc.-- -$3.91 $29.9M PTNPalatin Technologies-- -- -- -
What do Analysts Say About SNSE or PTN?
Sensei Biotherapeutics, Inc. has a consensus price target of $32.50, signalling upside risk potential of 280.02%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Sensei Biotherapeutics, Inc., analysts believe Palatin Technologies is more attractive than Sensei Biotherapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SNSESensei Biotherapeutics, Inc.1 0 0 PTNPalatin Technologies0 0 0 -
Is SNSE or PTN More Risky?
Sensei Biotherapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.
-
Which is a Better Dividend Stock SNSE or PTN?
Sensei Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sensei Biotherapeutics, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SNSE or PTN?
Sensei Biotherapeutics, Inc. quarterly revenues are --, which are larger than Palatin Technologies quarterly revenues of --. Sensei Biotherapeutics, Inc.'s net income of -$4.9M is higher than Palatin Technologies's net income of --. Notably, Sensei Biotherapeutics, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sensei Biotherapeutics, Inc. is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SNSESensei Biotherapeutics, Inc.-- -- -- -$4.9M PTNPalatin Technologies-- -- -- --
-
Which has Higher Returns SNSE or TOVX?
Theriva Biologics, Inc. has a net margin of -- compared to Sensei Biotherapeutics, Inc.'s net margin of --. Sensei Biotherapeutics, Inc.'s return on equity of -68.55% beat Theriva Biologics, Inc.'s return on equity of -171.04%.
Company Gross Margin Earnings Per Share Invested Capital SNSESensei Biotherapeutics, Inc.-- -$3.91 $29.9M TOVXTheriva Biologics, Inc.-- -$0.45 $9.5M -
What do Analysts Say About SNSE or TOVX?
Sensei Biotherapeutics, Inc. has a consensus price target of $32.50, signalling upside risk potential of 280.02%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 3349.98%. Given that Theriva Biologics, Inc. has higher upside potential than Sensei Biotherapeutics, Inc., analysts believe Theriva Biologics, Inc. is more attractive than Sensei Biotherapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SNSESensei Biotherapeutics, Inc.1 0 0 TOVXTheriva Biologics, Inc.1 1 0 -
Is SNSE or TOVX More Risky?
Sensei Biotherapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.818%.
-
Which is a Better Dividend Stock SNSE or TOVX?
Sensei Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sensei Biotherapeutics, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SNSE or TOVX?
Sensei Biotherapeutics, Inc. quarterly revenues are --, which are smaller than Theriva Biologics, Inc. quarterly revenues of --. Sensei Biotherapeutics, Inc.'s net income of -$4.9M is lower than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, Sensei Biotherapeutics, Inc.'s price-to-earnings ratio is -- while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sensei Biotherapeutics, Inc. is -- versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SNSESensei Biotherapeutics, Inc.-- -- -- -$4.9M TOVXTheriva Biologics, Inc.0.33x -- -- -$4.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
85
HUT alert for Dec 25
Hut 8 Corp. [HUT] is up 0.65% over the past day.
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
63
GPCR alert for Dec 25
Structure Therapeutics, Inc. [GPCR] is down 2.36% over the past day.
